Biotech Stock News: Gilead Inc Gets Another Major Boost
Good news flowed in at Gilead Sciences (GILD) with the FDA approving the company’s Harvoni for treating patients affected with chronic hepatitis C virus (HCV) genotype 1 infection. Harvoni is a once-daily combination treatment of Gilead’s highly successful HCV drug Sovaldi (sofosbuvir 400 mg) and ledipasvir (a NS5A inhibitor 90 mg). Following the FDA approval, Harvoni becomes the first single tablet regimen to treat HCV … Continue reading Biotech Stock News: Gilead Inc Gets Another Major Boost